Autopsy report · NCT00741741

TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.

“Strategic decision”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 1 year 4 months before it stopped.
• 20 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Tibotec Pharmaceuticals, Ireland

Sponsor type

Industry

Conditions

HIV-1

Interventions

TMC278

Participants

20

Trials that died the same way

• Rapid Amniotic Fluid (AF) Test and a Non-Invasive Vaginal Fluid (VF) Test
  “Business Strategic Decision” (92% match in meaning)
• Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
  “Strategic business decision” (91% match in meaning)
• Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
  “Strategic corporate decision” (90% match in meaning)
• A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
  “Company's strategic decision” (90% match in meaning)
• A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
  “Strategic considerations” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.